Phaseline

Companies › Tiziana Life Sciences

Tiziana Life Sciences: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 2; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Foralumab (TZLS-401)
T cell surface glycoprotein CD3 inhibitor
CD3E, CD3G, CD3DPhase 2Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; DementiaApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06890923Foralumab (TZLS-401)Phase 2Non-Active Secondary Progressive Multiple SclerosisNeurologyApr 2026
NCT06292923Foralumab (TZLS-401)Phase 2Secondary Progressive Multiple SclerosisNeurologySep 2026
NCT06489548Foralumab (TZLS-401)Phase 2DementiaNeurologyDec 2026
NCT06868628Foralumab (TZLS-401)Phase 2Multiple System AtrophyNeurologyApr 2027

Targets

CD3E (1) CD3G (1) CD3D (1)

Companies with the same targets

Johnson & Johnson (Janssen) Amgen Roche Regeneron Pharmaceuticals Pfizer Genmab AstraZeneca Sanofi Shine-On Biomedical Cullinan Therapeutics

Companies built like this

Abcuro Keros Therapeutics Acumen Pharmaceuticals Dianthus Therapeutics Y-mAbs Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.